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ABSTRACT
Background: WHO advocates 2-hour oral glucose
tolerance test (OGTT) for detecting diabetes mellitus
(DM). OGTT is the most sensitive method to detect DM
in patients with coronary artery disease (CAD).
Considered time consuming, the use of OGTT is
unsatisfactory. A 1-hour plasma glucose (1hPG) test
has not been evaluated as an alternative in patients
with CAD.
Objectives: To create an algorithm based on glycated
haemoglobin (HbA1c), fasting plasma glucose (FPG)
and 1hPG limiting the need of a 2-hour plasma
glucose (2hPG) in patients with CAD.
Methods: 951 patients with CAD without DM
underwent OGTT. A 2hPG≥11.1 mmol/L was the
reference for undiagnosed DM. The yield of HbA1c,
FPG and 1hPG was compared with that of 2hPG.
Results: Mean FPG was 6.2±0.9 mmol/L, and mean
HbA1c 5.8±0.4%. Based on 2hPG≥11.1 mmol/L 122
patients (13%) had DM. There was no value for the
combination of HbA1c and FPG to rule out or in DM
(HbA1c≥6.5%; FPG≥7.0 mmol/L). In receiver operating
characteristic analysis a 1hPG≥12 mmol/L balanced
sensitivity and specificity for detecting DM (both=82%;
positive and negative predictive values 40% and 97%).
A combination of FPG<6.5 mmol/L and
1hPG<11 mmol/L excluded 99% of DM. A combination
of FPG>8.0 mmol/L and 1hPG>15 mmol/L identified
100% of patients with DM.
Conclusions: Based on its satisfactory accuracy to
detect DM an algorithm is proposed for screening for
DM in patients with CAD decreasing the need for
a 2-hour OGTT by 71%.
INTRODUCTION
Diabetes mellitus (DM) has a considerable
negative impact on the prognosis of patients
with coronary artery disease (CAD), and its
presence should alert a clinician that inten-
sive, multifactorial treatment should be
initiated to counteract this high risk.1 A
meticulous use of evidence-based treatment
is, due to the high cardiovascular event rate
rewarding, with a substantially lower number
needed to treat to avoid future cardiovascu-
lar events than in patients with CAD only.2–4
Accordingly, it is important to identify DM
and even other forms of dysglycaemia such
as impaired glucose tolerance in patients
with CAD.1 5 6 Such patients have a high
prevalence of dysglycaemic conditions. It is a
concern that the presence of dysglycaemia
often remains undetected without proper
testing as shown more than a decade ago,
but still a problem as demonstrated by the
recent EUROpean Action on Secondary and
Primary prevention of coronary heart disease
In order to Reduce Events (EUROASPIRE
IV) survey.7–9
Current international guidelines endorse
the use of three methods to identify DM:
fasting plasma glucose (FPG), 2-hour post-
load plasma glucose (2hPG) from an oral
glucose tolerance test (OGTT) and glycated
haemoglobin (HbA1c).1 10–14 A report from
EUROASPIRE IV demonstrated that OGTT
was the most sensitive test when screening
for DM in patients with CAD while FPG in
combination with HbA1c left about a ﬁfth of
patients with DM unidentiﬁed.9 A disadvan-
tage with an OGTT is that it is time consum-
ing in comparison with the single blood test
needed for a FPG or HbA1c. Owing to this
Strengths and limitations of this study
▪ This algorithm limits the use of a full oral
glucose tolerance test with maintained accuracy.
▪ It is based on standardised examinations of a
large European population with coronary artery
disease.
▪ Blood glucose was analysed with a quality con-
trolled equipment and glycated haemoglobin in a
central laboratory.
▪ Great efforts were made to find suited popula-
tions for external validation without success, but
several studies evaluated 1-hour plasma glucose
in other cohorts with encouraging results.
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attempts to construct algorithms to limit the use of
OGTT have been made. An algorithm combining FPG
and HbA1c limited the use of OGTT in people with
impaired fasting glucose (IFG),15 and Gholap et al16 pre-
sented an algorithm based on HbA1c in patients with
acute coronary syndromes. Both these studies based
their cut point on ‘pragmatic’ grounds due to limited
availability of actual data.16 A 1-hour plasma glucose
(1hPG) test has been suggested as a time-saving option,
still retaining reasonably good accuracy in detecting type
2 DM when screening high-risk individuals in a general
population.17 18 An elevated 1hPG is associated with an
enhanced risk of future DM19 and cardiovascular
disease.20 To the best of our knowledge, no study has
evaluated the possibility to use 1hPG as a marker for
DM in patients with CAD.
The aim of the present study was to investigate an
algorithm based on a combination of HbA1c, FPG and
1hPG in order to limit the use of a 2hPG test without
losing the accuracy of detecting DM in patients with
CAD.
RESEARCH DESIGN AND METHODS
Study population
Details of EUROASPIRE IV, conducted in 24 European
countries from May 2012 to April 2013, have been pre-
sented elsewhere.9 This description relates to details of
special interest for the present study. The study popula-
tion comprises 951 patients (18–80 years) with stable
CAD and free from diabetes in whom FPG, HbA1c,
1hPG and 2hPG were determined.
Methods
Methods for recording and deﬁnitions of educational
level, current smoking, central obesity and blood pres-
sure have been described elsewhere.9
A standard OGTT was performed in the morning after
≥10 hours fasting. Plasma glucose was analysed locally
with a point-of-care technique (Glucose 201+, HemoCue,
Ängelholm, Sweden). Values obtained with the
HemoCue instrument were in 69% patients within 5%, in
91% patients within 10% and always within 14.3% of the
ID Gas Chromatography - Mass Spectrometry (GC-MS)
method.21 The values were converted from whole venous
blood to plasma applying the formula by Carstensen
et al:22 plasma glucose=0.558+0.119×whole blood glucose,
as used by the Euro Heart Survey on Diabetes and the
Heart.23
HbA1c was measured at the central laboratory
(Disease Risk Unit, National Institute for Health and
Welfare, Helsinki, Finland) with an immunoturbidi-
metric International Federation Clinical Chemists
(IFCC) aligned method (Abbot Architect analyser;
Abbott Laboratories, Abbott Park, Illinois, USA) in
fasting venous whole blood sampled in an EDTA tube.
Reference method
A 2hPG value ≥11.1 mmol/L (200 mg/dL) was used as
the reference for newly detected DM. The diagnostic
yield of HbA1c, FPG and 1hPG, alone or in combin-
ation, were compared with the outcome of the 2hPG.
DM was considered present if HbA1c was ≥6.5%
(52 mmol/L) or FPG≥7.0 mmol/mol (126 mg/dL)
according to the international recommendations.
Statistical analyses
Descriptive statistics (means, standard deviation (SD)
and proportions) were used to present information on
patient characteristics. The diagnostic performance of
1hPG as a marker of diabetes was studied by construct-
ing the empirical receiver operating characteristic
(ROC) curve. Each point on this curve represents a sen-
sitivity/speciﬁcity pair corresponding to a particular
1hPG threshold. The area under the ROC curve (AUC)
was calculated as a measure of how well 1hPG distin-
guishes between patients with, and without diabetes.
The optimal threshold 1hPG was obtained according to
the maximum Youden’s J statistic (=sensitivity+speciﬁcity
−1), a measure to ﬁnd an optimal balance between sen-
sitivity and speciﬁcity of a diagnostic test.
All statistical analyses were undertaken using SAS statis-
tical software release V.9.3 (SAS Institute, Cary, North
Carolina, USA).24
Written, informed consent was obtained from each
participant.
Patient involvement
This study was designed since patients with CAD fre-
quently have glucose perturbations that although prog-
nostically important but frequently left unrecognised.
An often claimed reason is that the use of an OGTT is
considered time consuming and thereby not convenient.
A simple screening tool may result in improved willing-
ness to screen and thereby be to the beneﬁt of many
patients. EUROASPIRE IV offered ideal possibilities to
perform the investigations needed. Although the proto-
col was not developed with patients or lay people
involved all participants were carefully informed of the
purpose with the glucose tolerance testing. Patients with
newly detected glucose perturbations were informed
and asked to discuss this ﬁnding with their ordinary
physician. The results of this investigation will be com-
municated via different channels including those suited
for patients and lay people and hopefully also inﬂuence
future management guidelines.
RESULTS
Clinical and laboratory characteristics of the 951 partici-
pants are presented in table 1. Their mean age was 63.4
(SD=101) years and 25% were women. The mean FPG
was 6.2±09 mmol/L (112±16 mg/dL), and the mean
HbA1c was 5.8±04% (40 mmol/mol). A total of 122/
951 (13%) patients had a 2hPG value ≥11.1 mmol/L
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(≥200 mg/dL) thereby fulﬁlling the deﬁnition of DM
used in the present analyses.
There was no clinically useful value for the combin-
ation of HbA1c and FPG to rule out or in diabetes
outside the established diagnostic criteria of
HbA1c≥6.5% (52 mmol/mol) or FPG≥7.0 mmol/L
(126 mg/dL; ﬁgure 1). In the ROC analysis evaluating
1hPG for the diagnosis of DM (2hPG value
≥11.1 mmol/L), a 1hPG of ≥12 mmol/L was identiﬁed
as the optimal balance between the sensitivity and speci-
ﬁcity with an AUC (95% CI) of 0.90 (0.87 to 0.92). The
sensitivity and speciﬁcity were both 82%, and the
positive and negative predictive values were 40% and
97%, respectively (ﬁgure 2).
When FPG<6.5 mmol/L and 1hPG<11 mmol/L was
used in combination it was possible to correctly exclude
99% of patients without DM. When FPG>8.0 mmol/L
was combined with 1hPG>15 mmol/L 100% of the
patients with DM were correctly identiﬁed (ﬁgure 3).
Based on these results a clinical algorithm for the
identiﬁcation of DM in patients with CAD is proposed
that signiﬁcantly limits the use of 2hPG without losing
the sensitivity and speciﬁcity provided by postchallenge
glucose assessment (ﬁgure 4).
DISCUSSION
The current practice to screen for DM by means of
HbA1c and FPG in combination does not exclude DM
although it may verify its presence in patients with CAD.
The combined use of HbA1c, FPG and 1hPG following
a standard 75 g oral glucose load did turn out as a clinic-
ally useful screening tool by means of which it was
almost completely possible to exclude the presence of
DM determined by 2hPG. Therefore, it is proposed that
this time-saving algorithm should be applied to either
detect or exclude DM with appropriate clinical accuracy
in patients with CAD.
DM is a serious condition that can cause serious
microvascular complications in addition to macrovascu-
lar disease if not managed well.1 The presence of DM
requires effective control of risk factors such as blood
pressure, blood lipids and hyperglycaemia and should
therefore alert the responsible clinician to take stringent
actions to reach guideline targets in risk factor manage-
ment.2–4
A combination of different tests has been proposed to
identify individuals with diabetes, or at high risk of devel-
oping diabetes, at a population level.17 25 These studies
did not include a population of patients with veriﬁed
CAD. The recent report from EUROASPIRE IV demon-
strated that screening coronary patients with HbA1c,
and FPG alone left one in ﬁve patients with undetected
DM.9 Yet, this combination alone has been advocated as
sufﬁcient for diagnosing DM in patients with CAD.26 27
In contrast, the American Diabetes Association (ADA)
in their 2016 recommendations for classiﬁcation and
diagnosis of DM do not prioritise HbA1c as the sole
diagnostic tool and recommends an OGTT. ADA states
that even if HbA1c has several advantages compared
with the FPG and OGTT, these advantages may be offset
by its ‘lower sensitivity at the designated cut point,
greater cost and limited availability of testing in certain
regions’ and, in addition that ‘numerous studies have
conﬁrmed that, compared with FPG cut points and
HbA1c, the 2hPG value diagnoses more people with
diabetes’.28
The combination of HbA1c and FPG did correctly
identify 83% of the patients with previously undiagnosed
DM in EUROASPIRE IV.9 Considering the practicality of
Table 1 Basic characteristics of 951 patients with CAD
without diabetes in whom FPG, 1hPG and 2hPG was
available
Variable
Patient number
951
Age (years)
Mean (SD) 63.4 (10.1)
<50 11 (102)
50–59 25 (238)
60–69 35 (334)
>70 29 (277)
Sex
Women 25 (241)
Men 75 (710)
Low educational level 10 (94; n=944)
Current smoking 14 (131)
BMI, kg/m2
<25 19 (179)
≥25 and <30 46 (437)
≥30 35 (334)
Central obesity 59 (546; n=930)
Blood pressure (SBP/DBP≥140/
90 mm Hg)
33 (311)
Plasma glucose (mmol/L)
≥7 15 (142)
Fasting (mean±SD) 6.2±0.87
1 hour postload 10.3±2.92
2 hours postload 8.0±2.77
HbA1c (%)
≥6.5 (≥48 mmol/mol) 7 (61; n=918)
Mean (%±SD) 5.8±0.44
Pharmacological treatment
ASA/antiplatelets 94 (892)
β-blockers 82 (778)
ACE-inhibitors 60 (564)
AT-II receptor antagonists 14 (136)
Diuretics 24 (230)
Statins 87 (818)
Low physical activity (IPAQ) 64 (591; n=918)
Values are per cent (n) if not otherwise stated. N within
brackets=number of observations in case of incomplete
information.
1hPG, 1-hour plasma glucose; 2hPG, 2-hour plasma glucose;
ASA, acetylsalicylic acid or Aspirin; AT, Angiotensin II; BMI, body
mass index; CAD, coronary artery disease; DBP, diastolic blood
pressure; FPG, fasting plasma glucose; HbA1c, glycated
haemoglobin; IPAQ, International Physical Activity Scale;
SBP, systolic blood pressure.
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Figure 1 Panel A—Patients with diabetes (2hPG≥11.1 mmol/L) who fulfil the criteria for diabetes according to (A) HbA1c≥6.5%
(48 mmol/mol); (B) FPG≥7.0 mmol/L and HbA1c≥6.5%; (C) FPG<7.0 mmol/L and HbA1c<6.5%; (D) FPG≥7.0 mmol/L. Panel B
—Patients free from diabetes (2hPG≤11.1 mmol/L) that have diabetes according to (A) HbA1c≥6.5%; (B) FPG≥7.0 mmol/L and
HbA1c≥6.5%; (C) no test; (D) FPG≥7.0 mmol/L. Dotted lines delineate: horizontal an HbA1c level ≥6.5%; vertical a
FPG≥7.0 mmol/L. 2hPG, 2-hour plasma glucose; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.
4 Gyberg V, et al. BMJ Open 2016;6:e013835. doi:10.1136/bmjopen-2016-013835
Open Access
this combination, it was applied as a ﬁrst step in the
presently proposed clinical algorithm for detecting DM
in patients with CAD (ﬁgure 4). The use of the 1hPG in
the algorithm made it possible to exclude DM with a
high speciﬁcity. It halved the total time for the OGTT
for about two-thirds of the patients. If the combination
of FPG, HbA1c and 1hPG is inconclusive, the recom-
mendation is to measure a 2hPG, which will identify the
remaining cases of DM. Applying the proposed algo-
rithm means that 19% of patients with CAD will only
need investigation with FPG, and HbA1c, 81% will need
a 1hPG, and only 29% will require a 2hPG saving time
and resources. The use of the suggested algorithm
requires immediate access to the glucose values by
means of a point-of-care device with high accuracy such
as the HemoCue.21 In screening for undiagnosed DM,
the use of validated point-of-care glucose analysers are
useful, since it is possible to decide after each step
whether there is a need for further glucose testing. In
addition, it is possible to institute proper clinical man-
agement of patients with CAD diagnosed with DM in
order to reduce the risk of microvascular and macrovas-
cular disease. It could also be potentially used in
patients with cerebrovascular and peripheral artery
disease who have a similar prevalence of diabetes as in
the present CAD population.29
This algorithm also identiﬁes patients with IFG but,
apart from the minority of patients requiring a 2hPG,
does not detect impaired glucose tolerance. It was indeed
impossible to deﬁne a 1hPG that identiﬁed such indivi-
duals. Patients with impaired glucose tolerance are more
likely to develop cardiovascular events than those with
IFG, and the equivalent prognostic information derived
by means of HbA1c is limited.30 31 In addition, HbA1c
between 39 and 47 mmol/mol (5.7–6.4%) is less sensitive
than IFG or impaired glucose tolerance to detect indivi-
duals with β-cell dysfunction, and insulin resistance.32
Strengths and limitations
A main strength of EUROASPIRE IV is that data are
based on interviews and standardised examinations
rather than data from medical records in a large cross-
sectional European population of well-characterised
individuals with CAD. All four tests FPG, 1hPG, 2hPG
and HbA1c were collected at the same time.
Figure 2 In a ROC analysis evaluating 1hPG for diagnosing
diabetes (defined by 2hPG value ≥11.1 mmol/L), 12 mmol/L
was identified as the optimal balance between sensitivity and
specificity with an AUC (95% CI) of 0.90 (0.87 to 0.92). The
sensitivity and specificity were both 82%, while the positive
and negative predictive values were 40% and 97%,
respectively. 1hPG, 1-hour plasma glucose; 2hPG, 2-hour
plasma glucose; AUC, area under the ROC curve; ROC,
receiver operating characteristic.
Figure 3 The combination of FPG<6.5 mmol/L and
1hPG<11.0 mmol/L correctly excluded diabetes in 99% of
patients in this category. 1hPG, 1-hour plasma glucose; FPG,
fasting plasma glucose; HbA1c, glycated haemoglobin.
Figure 4 Proposed clinical algorithm for assessing
glucometabolic status (see text for further explanation). 1hPG,
1-hour plasma glucose; 2hPG, 2-hour plasma glucose; FPG,
fasting plasma glucose; HbA1c, glycated haemoglobin.
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Standardised central training was given to the staff per-
forming the blood sampling, and glucose measure-
ments. All centres used the HemoCue 201+ equipment
for glucose determination with appropriate quality
control. HbA1c was determined in a central laboratory.
The use of OGTT as the gold standard for diagnosing
DM has been criticised besides from being time consum-
ing also for reproducibility.33 In the current population
it does, however, provide accurate information during a
time period of at least 1 year.34
An important limitation is that the algorithm has not
yet been validated in another population with CAD. On
the other hand, several other studies evaluated the use-
fulness of 1hPG as a diagnostic tool of diabetes or pre-
dictor of future development of diabetes in other
populations with encouraging results.17–20 Efforts were
indeed made to ﬁnd a suited population for external val-
idation, that is, of patients with CAD and FPG, 1hPG,
2hPG and HbA1c available, but no such population
could be identiﬁed. The algorithm will, however, be
tested in the coming EUROASPIRE V survey planned to
start during 2016. For logistical reasons, FPG, 2hPG and
HbA1c were only measured once. According to present
recommendations, one positive test is not sufﬁcient to
ﬁrmly establish the diagnosis of DM, which should be
based on at least two separate measurements. The
present algorithm based on one blood test could be
further reﬁned with a second independent blood test.
This study was performed on a European population
and needs to be studied in other ethnic groups before it
can be accepted as generally applicable
CONCLUSION
A time-saving and resource-saving algorithm for screening
for DM in a population of patients with CAD is proposed.
It will decrease the need for a full 2-hour long OGTT to
29% of the population with satisfactory clinical accuracy.
From a clinical perspective, the application of the new
algorithm will leave about 1% of patients with DM
undetected but this is considerably better than the much
larger proportion left undetected without an OGTT.
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